Therapeutic Focus - Gastrointestinal and Inflammation | Takeda Pharmaceuticals
GI and Inflammation
Our ambition is to help people living with gastrointestinal (GI) and inflammatory diseases reclaim their lives. Conditions like inflammatory bowel disease (IBD) and psoriasis can disrupt daily living with unpredictable flare-ups, painful and stigmatizing symptoms, and the constant burden of worry and shame.
We believe patients deserve more treatment options, better health and better lives.
With nearly 35 years of experience in inflammation and immunology, we are building on our GI legacy while expanding into areas of high unmet need, from psoriatic disease to other immune-mediated inflammatory conditions.
We focus where patient need intersects with promising science, using artificial intelligence and machine learning to accelerate discovery and generate deeper insights. By working closely with scientists, healthcare professionals, patient organizations, and partners, we are advancing critical research across multiple disease areas—because patients are still looking for treatments that may work for them.
Disease areas
Dermatology and rheumatology: Psoriasis, psoriatic arthritis, hidradenitis suppurativa, and vitiligo
GI and liver disease: Crohn’s disease, ulcerative colitis, celiac disease, alpha-1 antitrypsin deficiency-associated liver disease and primary sclerosing cholangitis
Hematology and renal disease: Immune thrombocytopenia and IgA nephropathy
